Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 226.00 | Gross Profit |
0.00 | -537.00K | -466.00K | -129.00K | -4.77K | EBIT |
-62.38M | -78.19M | -67.59M | -35.83M | -8.33M | EBITDA |
-62.38M | -66.33M | -62.84M | -35.70M | -8.32M | Net Income Common Stockholders |
-49.59M | -66.86M | -58.62M | -35.53M | -8.28M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
245.48M | 281.80M | 330.39M | 384.06M | 36.09M | Total Assets |
252.09M | 289.64M | 341.14M | 390.56M | 36.52M | Total Debt |
1.53M | 3.05M | 3.69M | 3.63M | 0.00 | Net Debt |
-21.03M | -18.15M | -22.81M | -294.94M | -2.38M | Total Liabilities |
10.00M | 11.96M | 13.83M | 8.43M | 47.83M | Stockholders Equity |
242.10M | 277.69M | 327.31M | 382.13M | -11.31M |
Cash Flow | Free Cash Flow | |||
-43.45M | -58.82M | -52.23M | -30.91M | -8.74M | Operating Cash Flow |
-43.10M | -58.56M | -51.32M | -29.38M | -8.67M | Investing Cash Flow |
43.95M | 52.54M | -220.99M | -53.64M | -33.56M | Financing Cash Flow |
513.00K | 724.00K | 235.00 | 379.21K | 44.53M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
48 Neutral | $187.69M | ― | 322.49% | ― | -33.83% | 27.89% | |
46 Neutral | $2.84B | ― | -19.20% | ― | -89.95% | -123.71% | |
46 Neutral | $1.76B | ― | -43.94% | ― | -83.18% | -144.95% | |
41 Neutral | $688.91M | ― | -54.00% | ― | 59.55% | 3.09% | |
39 Underperform | $93.76M | ― | -98.10% | ― | -58.64% | -40.05% | |
32 Underperform | $204.63M | ― | -19.08% | ― | ― | 26.63% |
Design Therapeutics, Inc. has updated its corporate presentation to be used in meetings with investors, analysts, and others, which has been attached to a Current Report on Form 8-K. This update, although furnished for informational purposes, is not deemed filed under the Securities Exchange Act or the Securities Act, thus limiting its formal legal implications.